Seres Therapeutics Inc. (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities analysts also recently commented on MCRB. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 8th. Leerink Swann restated a “buy” rating and issued a $43.00 price target on shares of Seres Therapeutics in a research report on Thursday, July 14th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, July 19th. HC Wainwright began coverage on shares of Seres Therapeutics in a research report on Friday, July 29th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Bank of America Corp. cut shares of Seres Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $31.57.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB) opened at 11.425 on Wednesday. The company’s market capitalization is $460.13 million. Seres Therapeutics has a 12 month low of $8.05 and a 12 month high of $44.51. The stock’s 50 day moving average is $11.82 and its 200-day moving average is $22.90.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The company had revenue of $3 million for the quarter, compared to analyst estimates of $4.20 million. Seres Therapeutics’s revenue was up NaN% compared to the same quarter last year. During the same period last year, the firm posted ($1.45) earnings per share. On average, analysts expect that Seres Therapeutics will post ($2.33) EPS for the current year.

In other news, insider John G. Aunins sold 9,390 shares of the stock in a transaction on Monday, August 29th. The shares were sold at an average price of $10.87, for a total transaction of $102,069.30. Following the completion of the sale, the insider now directly owns 192,125 shares in the company, valued at $2,088,398.75. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Michele Trucksis sold 38,064 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $35.14, for a total transaction of $1,337,568.96. Following the sale, the insider now owns 38,064 shares of the company’s stock, valued at $1,337,568.96. The disclosure for this sale can be found here. Insiders own 41.90% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its stake in Seres Therapeutics by 68.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 39,470 shares of the company’s stock valued at $1,147,000 after buying an additional 15,978 shares during the period. American Century Companies Inc. bought a new stake in Seres Therapeutics during the second quarter worth approximately $3,163,000. Metropolitan Life Insurance Co. NY boosted its stake in Seres Therapeutics by 109.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 13,550 shares of the company’s stock worth $394,000 after buying an additional 7,083 shares during the last quarter. Flagship Ventures Fund IV General Partner LLC bought a new stake in Seres Therapeutics during the second quarter worth approximately $368,438,000. Finally, Opaleye Management Inc. bought a new stake in Seres Therapeutics during the second quarter worth approximately $1,670,000. Institutional investors own 78.28% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

5 Day Chart for NASDAQ:MCRB

Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.